Perspective announces first patient dosed in Phase 1 study of VMT-alpha-NET

Perspective Therapeutics announced that the first patient was dosed at the University of Iowa in an investigator-initiated Phase 1 trial evaluating the safety of VMT-alpha-NET, a targeted alpha-particle therapy, in patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors. The patients being enrolled in the study have either progressed or relapsed after previous therapies, including currently approved peptide receptor radionuclide therapies. “We are delighted that this innovative investigator-initiated study has commenced in refractory and relapsed neuroendocrine tumor patients,” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics. “Along with our company-sponsored first-line trial that is well underway, we expect that the data gathered during this investigator initiated trial from this previously treated population will increase the number of patients who might be available to receive VMT-alpha-NET in the future. The first-line PRRT setting has been commercially validated by DOTATATE, and there has also recently been a great deal of value ascribed to development in the PRRT-relapsed setting, so we look forward to seeing the results of these investigations.”